FibroGen Inc (FGEN) : Opaleye Management scooped up 5,000 additional shares in FibroGen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 330,000 shares of FibroGen Inc which is valued at $6,322,800.FibroGen Inc makes up approximately 3.62% of Opaleye Management’s portfolio.
Other Hedge Funds, Including , Norges Bank added FGEN to its portfolio by purchasing 322,326 company shares during the most recent quarter which is valued at $6,175,766.Ubs Asset Management Americas Inc boosted its stake in FGEN in the latest quarter, The investment management firm added 78,810 additional shares and now holds a total of 237,326 shares of FibroGen Inc which is valued at $4,378,665. Eam Investors sold out all of its stake in FGEN during the most recent quarter. The investment firm sold 121,509 shares of FGEN which is valued $2,418,029.Smith Asset Management Group Lp reduced its stake in FGEN by selling 310 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 10,670 shares of FGEN which is valued at $199,529. FibroGen Inc makes up approx 0.01% of Smith Asset Management Group Lp’s portfolio.
FibroGen Inc closed down -0.3 points or -1.67% at $17.63 with 2,29,051 shares getting traded on Monday. Post opening the session at $17.99, the shares hit an intraday low of $17.44 and an intraday high of $18.045 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
FibroGen Inc. is a research-based biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapeutic agents. Its lead product candidate is roxadustat or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHs) in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). The Company’s second product candidate FG-3019 is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) pancreatic cancer and liver fibrosis. Roxadustat is a HIF-PH inhibitor that acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-5200 is a corneal implant. Its product FG-3019 blocks FG-3019 blocks CTGF (CTGF). FG-6874 is a HIF-PH inhibitor. FG-8205 is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack.